Armin Koch

List of Publications by Year
in descending order

54	1,783	304368 22	288905 40
papers	citations	h-index	g-index

56	56	56	3011
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood, 2015, 125, 1091-1097.	0.6	197
2	Methods for evidence synthesis in the case of very few studies. Research Synthesis Methods, 2018, 9, 382-392.	4.2	132
3	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infectious Diseases, The, 2019, 19, 275-286.	4.6	128
4	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respiratory Medicine, 2016, 114, 27-37.	1.3	113
5	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infectious Diseases, The, 2017, 17, 215-222.	4.6	109
6	Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine, 2016, 16, 70.	0.8	81
7	Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequencesâ€“Comorbidities Network Study. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 189-197.	2.5	81
8	No solution yet for combining two independent studies in the presence of heterogeneity. Statistics in Medicine, 2015, 34, 2476-2480.	0.8	57
9	Rationale and design of the DIGITâ€HF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq1 1 0.784314 rgBT /O Heart Failure, 2019, 21, 676-684.	2.9	51
10	Antiâ€“factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood, 2016, 127, 2289-2297.	0.6	48
11	Digoxinâ€“mortality: randomized vs. observational comparison in the DIG trial. European Heart Journal, 2019, 40, 3336-3341.	1.0	48
12	Nonâ€invasive fibrosis score for hepatitis delta. Liver International, 2017, 37, 196-204.	1.9	42
13	Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. European Heart Journal, 2017, 38, ehw577.	1.0	40
14	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E â€“ The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	1.8	39
15	Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet Journal of Rare Diseases, 2018, 13, 206.	1.2	37
16	Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respiratory Research, 2019, 20, 151.	1.4	33
17	The use of external controls: To what extent can it currently be recommended?. Pharmaceutical Statistics, 2021, 20, 1002-1016.	0.7	33
18	Respiratory tract exacerbations revisited: Ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. Pediatric Pulmonology, 2015, 50, S57-65.	1.0	29

#	Article	IF	Citations
19	A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Trials, 2016, 17, 312.	0.7	28
20	Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respiratory Research, 2017, 18, 171.	1.4	27
21	Effects of ultrafine particles on the allergic inflammation in the lung of asthmatics: results of a double-blinded randomized cross-over clinical pilot study. Particle and Fibre Toxicology, 2014, 11, 39.	2.8	26
22	Confirmatory Clinical Trials with an Adaptive Design. Biometrical Journal, 2006, 48, 574-585.	0.6	25
23	Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respiratory Research, 2016, 17, 81.	1.4	25
24	Reliably Basing Conclusions on Subgroups of Randomized Clinical Trials. Journal of Biopharmaceutical Statistics, 2014, 24, 42-57.	0.4	21
25	Perioperative Bromelain Therapy after Wisdom Teeth Extraction â€“ A Randomized, Placeboâ€Controlled, Doubleâ€Blinded, Threeâ€Armed, Crossâ€Over Doseâ€Finding Study. Phytotherapy Research, 2016, 30, 2012-2019.	2.8	21
26	The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. Frontiers in Psychiatry, 2020, 11, 575826.	1.3	21
27	How to use prior knowledge and still give new data a chance?. Pharmaceutical Statistics, 2018, 17, 329-341.	0.7	20
28	Unblinded Adaptive Statistical Information Design Based on Clinical Endpoint or Biomarker. Statistics in Biopharmaceutical Research, 2013, 5, 293-310.	0.6	19
29	The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. International Journal of COPD, 2017, Volume 12, 3437-3448.	0.9	19
30	No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses. Journal of Clinical Epidemiology, 2010, 63, 1305-1307.	2.4	18
31	Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard. Journal of Clinical Epidemiology, 2016, 78, 73-82.	2.4	17
32	Risk factors for death in kidney transplant patients: analysis from a large protocol biopsy registry. Nephrology Dialysis Transplantation, 2019, 34, 1171-1181.	0.4	17
33	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Frontiers in Cardiovascular Medicine, 2020, 7, 51.	1.1	16
34	Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respiratory Research, 2017, 18, 60.	1.4	15
35	Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans. Scientific Reports, 2019, 9, 3641.	1.6	15
36	Short term results of dynamic splinting for hallux valgus â€” A prospective randomized study. Foot and Ankle Surgery, 2020, 26, 146-150.	0.8	15

#	Article	IF	Citations
37	Fallback tests for coâ€primary endpoints. Statistics in Medicine, 2016, 35, 2669-2686.	0.8	13
38	Applicability and added value of novel methods to improve drug development in rare diseases. Orphanet Journal of Rare Diseases, 2018, 13, 200.	1.2	12
39	Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples - a multicentre phase 3 diagnostic accuracy study. BMC Nephrology, 2015, 16, 153.	0.8	10
40	Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease. Orphanet Journal of Rare Diseases, 2017, 12, 140.	1.2	10
41	Commentary: On the levels of patient selection in registry-based randomized controlled trials. Trials, 2019, 20, 100.	0.7	10
42	Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols. Pharmaceutical Statistics, 2019, 18, 636-644.	0.7	9
43	Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients. Trials, 2020, 21, 643.	0.7	9
44	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial. Transplantation Direct, 2022, 8, e1316.	0.8	7
45	Microbiota-associated Risk Factors for Clostridioides difficile Acquisition in Hospitalized Patients: A Prospective, Multicentric Study. Clinical Infectious Diseases, 2021, 73, e2625-e2634.	2.9	6
46	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. PLoS ONE, 2015, 10, e0128069.	1.1	5
47	A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients. Orphanet Journal of Rare Diseases, 2017, 12, 102.	1.2	5
48	Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke. Pharmaceutical Statistics, 2019, 18, 140-144.	0.7	5
49	Why Are Some Meta-Analyses More Credible Than Others?. Drug Information Journal, 2001, 35, 1019-1030.	0.5	4
50	ACEMg-mediated hearing preservation in cochlear implant patients receiving different electrode lengths (PROHEARING): study protocol for a randomized controlled trial. Trials, 2016, 17, 394.	0.7	4
51	Potential impact of <scp>COVID</scp>â€19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the <scp>CANNAâ€TICS</scp> study. Pharmaceutical Statistics, 2021, 20, 675-691.	0.7	4
52	COVID-19 hits a trial: Arguments against hastily deviating from the plan. Contemporary Clinical Trials, 2020, 98, 106155.	0.8	3
53	The Benefit of Baseline Stagingâ€“Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage. Anticancer Research, 2016, 36, 4909-4914.	0.5	1
54	Does it help that efficacy has been proven once we start discussing (added) benefit?. Biometrical Journal, 2016, 58, 89-103.	0.6	0